- Home
- CDTX vs PSNL Comparison
CDTX vs PSNL Comparison
Compare CDTX & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTX
- PSNL
- Stock Information
- Founded
- CDTX 2012
- PSNL 2011
- Country
- CDTX United States
- PSNL United States
- Employees
- CDTX N/A
- PSNL N/A
- Industry
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- PSNL Medical Specialities
- Sector
- CDTX Health Care
- PSNL Health Care
- Exchange
- CDTX Nasdaq
- PSNL Nasdaq
- Market Cap
- CDTX 242.5M
- PSNL 245.1M
- IPO Year
- CDTX 2015
- PSNL 2019
- Fundamental
- Price
- CDTX $20.53
- PSNL $3.47
- Analyst Decision
- CDTX Strong Buy
- PSNL Strong Buy
- Analyst Count
- CDTX 6
- PSNL 4
- Target Price
- CDTX $32.20
- PSNL $6.81
- AVG Volume (30 Days)
- CDTX 86.5K
- PSNL 620.1K
- Earning Date
- CDTX 11-07-2024
- PSNL 11-06-2024
- Dividend Yield
- CDTX N/A
- PSNL N/A
- EPS Growth
- CDTX N/A
- PSNL N/A
- EPS
- CDTX N/A
- PSNL N/A
- Revenue
- CDTX $44,653,000.00
- PSNL $87,489,000.00
- Revenue This Year
- CDTX N/A
- PSNL $15.76
- Revenue Next Year
- CDTX N/A
- PSNL $4.02
- P/E Ratio
- CDTX N/A
- PSNL N/A
- Revenue Growth
- CDTX 44.48
- PSNL 24.05
- 52 Week Low
- CDTX $10.00
- PSNL $1.12
- 52 Week High
- CDTX $24.99
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- CDTX 55.06
- PSNL 46.18
- Support Level
- CDTX $21.15
- PSNL $3.36
- Resistance Level
- CDTX $24.99
- PSNL $4.14
- Average True Range (ATR)
- CDTX 2.10
- PSNL 0.27
- MACD
- CDTX -0.15
- PSNL 0.04
- Stochastic Oscillator
- CDTX 41.16
- PSNL 54.22
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.